Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years,...
Saved in:
Main Authors: | Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/15/1/140 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research Progress in Small-Molecule Detection Using Aptamer-Based SERS Techniques
by: Li Zheng, et al.
Published: (2025-01-01) -
Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology
by: Rupal Dhariwal, et al.
Published: (2025-01-01) -
Association between SPISE and NAFLD in patients with type 2 diabetes
by: Hongyan Zhao, et al.
Published: (2025-01-01) -
Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies
by: Elisa Monti, et al.
Published: (2025-01-01) -
Editorial: Exploring novel approaches to small molecule kinase inhibitors in cancer treatment
by: Anna Carbone, et al.
Published: (2025-02-01)